NUVISAN and Bayer Create New Research Unit in Berlin

Published on: 

Applied Clinical Trials

NUVISAN has agreed with Bayer to integrate large parts of Bayer’s Berlin-based small molecule research unit and complements hereby its services in the field of preclinical research. NUVISAN is an international service provider for clinical studies, laboratory services and contract manufacturing (CRO / CDMO) with several sites and clinics in Germany and France. The strategic partnership will lay the foundation for a new research entity to be established by NUVISAN in Berlin and confirms the longstanding cooperation between the two companies. 

“With NUVISAN we have found an excellent partner with a clear plan to build up a strong full- fledged research unit in Berlin together with our dedicated team of scientists,” said Dr. Joerg Moeller, Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development. “NUVISAN shares our vision that the new research center can become an important player in research partnering based on the joint know-how and the capabilities of our highly qualified scientists”. 

The partnered Berlin-based research unit with around 400 workplaces comprises of a fully operational team specialized in small molecule research. The research center comes with capabilities and capacities spanning the entire drug discovery value chain, including Lead Discovery, Medicinal Chemistry, Pharmacology, Drug Metabolism & Pharmacokinetics and Investigational Toxicology. 


"With these new drug discovery capabilities and capacities in the field of drug discovery, we do not only welcome a high-performance research team, but also obtain access to excellent specialty know-how and technology and continuously expand the range of services," says Dr. Dietrich Bruchmann, CEO and managing partner of NUVISAN. “The acquisition of the research unit and our commitment to the location at the Bayer R&D campus will create an operational hub in the scientific excellence cluster Berlin and allow the combined businesses to significantly accelerate the drug development process from discovery to clinical trials. There is hardly any overlap in our range of services, so that we can immediately benefit from a variety of synergies and operational advantages through the new research center.” 

NUVISAN and Bayer will cooperate closely in the coming years to build the new research center. The transaction is expected to close mid of 2020. Financial terms were not disclosed.